Patients in Stamford, Greenwich, Fairfield County, and throughout Connecticut can call 203-348-8805 to discuss whether medical weight loss, GLP-1 therapy, semaglutide, tirzepatide, or another physician-supervised option may be appropriate
2020), with clinical benefits detailed in cardiovascular outcome studies (see Sect
reported that cleavage products derived from GLP-1 reduced tubulointerstitial renal damage, lowered the expression of tubular injury markers, and attenuated the renal accumulation of macrophages and T cells (Moellmann et al., 2018)
GLP-1 maintenance refers to the phase after active weight loss when medication dosing is adjusted to help stabilize appetite, metabolism, and weight